This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).
Therapeutic Indication
### Therapeutic indication Treatment of adults, adolescents and children, six years or older with diabetes mellitus, where treatment with insulin is required.
Therapeutic Area (MeSH)
ATC Code
A10AB06
ATC Item
insulin glulisine
Pharmacotherapeutic Group
Drugs used in diabetes
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| insulin glulisine | N/A | 谷赖胰岛素 |
EMA Name
Apidra
Medicine Name
Apidra
Aliases
N/ANo risk management plan link.
